CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
NEWARK, CA -- (Marketwired) -- 03/23/15 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that it will host a Key Opinion Leader breakfast focused on gout, current treatment options and the company's Phase 2 drug candidate arhalofenate. The event and live webcast will take place on Friday, March 27 from 8:00 am-9:30 am Eastern Time in New York City.
The meeting will feature a keynote presentation by key opinion leader N. Lawrence Edwards, MD, MACP, FACR, Professor of Medicine in the Division of Rheumatology and Clinical Immunology, and the Program Director and Vice Chairman of the Department of Medicine at the University of Florida in Gainesville. Members of the CymaBay executive management team will provide an overview of the Company's operations and ongoing clinical development work with its lead product candidate for the treatment of gout, arhalofenate, which has completed multiple Phase 2 studies. They will also be available for Q&A.
This event is intended for institutional investors and sell-side analysts. To reserve a place, please contact Veronica Molina at 212-915-2567, or via email at vmolina@lifesciadvisors.com. A live webcast and subsequent replay of the event will also be available at http://lifesci.rampard.com/20150327/reg.jsp, and will be accessible through the Investors section of the Company's website at http://ir.cymabay.com/events.
In addition to Dr. Edwards' many leadership roles within the Division of Rheumatology and Clinical Immunology and in the Department of Medicine at the University of Florida, he has long had a primary clinical interest in gout, hyperuricemia, and purine metabolism. He is an active member of many professional organizations, including the American College of Rheumatology, the Association of Program Directors in Internal Medicine. Dr. Edwards is on the Executive Board of the Florida Chapter of American College of Physicians, the Co-chair of the Gout Interest Group for OMERACT (Outcome Measures in Rheumatology) and the Chairman and CEO of the Gout and Uric Acid Education Society.
About CymaBay
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in multiple Phase 2 gout studies. In gout patients, arhalofenate is intended to prevent painful flares in joints while at the same time promoting excretion of uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. CymaBay's second product candidate, MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay is in the process of initiating a pilot study of MBX-8025 in patients with homozygous familial hypercholesterolemia.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
investors@cymabay.com
Source: CymaBay Therapeutics
Released March 23, 2015